A “revolutionary” lung cancer drug which stops tumours growing by targeting the so-called “Death Star” gene mutation will be available on the NHS within weeks, it has been announced. It comes after 40 years of research into the mutation on the KRAS gene, which is present in a quarter of all tumours. The mutation gained the moniker “Death Star” due to its impenetrable nature and spherical shape.
↧